Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Hisse Senetlerindeki Sıralama #33956
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Hisse Fiyatı
$17.15
Son senkronizasyon: 2026-08-03
Piyasa Değeri
$6.51M
Değişim (1 gün)
9.80%
Değişim (1 yıl)
289.77%
Ülke
US
Ticaret Galera Therapeutics, Inc. (GRTX)

Kategori

Galera Therapeutics, Inc. (GRTX) için kazanç
Mar 2026 itibarıyla kazanç TTM: $149.04M
Galera Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $149.04M'dir. 2023 yılında şirket $-59.08M kazanç elde etti, bu 2022 yılındaki $-62.29M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Galera Therapeutics, Inc. için kazanç geçmişi 2017 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B 3,439.37%
US
$1.95B 1,208.85%
NL
- -
CH
- -
KR
$3.01B 1,916.79%
BE